A New Haven startup biopharma with Yale ties has gotten $6.6 million from investors, including Connecticut's technology investment arm.
Connecticut Innovations Inc. announced Monday it put $1.5 million into New Haven Pharmaceuticals Inc. through its Eli Whitney Fund. CI has a seat on the pharma's board.
Others, including Yale University, EJ Funds, Kuzari Group and Advantage Capital Partners, put up the $5.1 million balance, officials said.
Using technology licensed from Yale, the startup is working on a line of drugs that includes a treatment for heart disease and another for patients with acid-reflux ailments.
Its CEO is Patrick Fourteau, former president and CEO of Shionogi Pharma and Sciele Pharma.
Serial Connecticut biotech investor Harry H. Penner Jr. is New Haven Pharma's co-founder and executive chairman. Penner is former CEO of Neurogen Corp. in Branford.
Nancy Motola, its vice president of regulatory affairs, has overseen previous Food & Drug Administration applications at other biopharmas, including Connecticut's Alexion Pharmaceuticals and Rib-X Pharmaceuticals, and Bayer.